Shivalik Rasayan Limited (SHIVALIK) Fair Value & Analysis
Basic Materials · IN · Market cap ₹3.6B
Fair value as of: Jul 3, 2026
From 16 valuation models · updated today
Share price −6.4% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹209.50 – ₹612.26 · fair‑value band ₹115.58 – ₹209.16 · the ₹226.38 price screens above the ₹183.25 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Shivalik Rasayan Limited (SHIVALIK) currently trades at ₹226.38, while our model-based Fair Value estimate is ₹183.25 — implying the stock looks roughly 19.1% overvalued today. We read business quality at 36/100 (below-average quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Shivalik Rasayan Limited generated revenue of ₹3.7B at a net margin of 3.3%. Revenue grew 53.1% year over year. It earns a return on equity of 3.2%. Net debt stands at ₹793M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Shivalik Rasayan Limited produces and sells chemicals for the protection of plants in India. The company offers Dimethoate technical used in the preparation of formulations for use in the control of various insects and mites; and Malathion technical, an organophosphorus based contact insecticide used in the agricultural production of various food/feed crops. It also provides insecticides, such as CHLORANTRANILIPROLE, CHLOREFENAPYR, PYMETROZINE, NOVALURON, and BIFENTHRIN; and fungicides, including AZOXYSTROBIN, TRIFLOXYSTOBIN, and KRESOXIM-METHYL products. It also manufactures organophosphorus-based insecticides and chemicals. In addition, it develops and manufactures active pharmaceutical ingredients in oncology, ARVs, cardiovascular, metabolic disorders, and immunology; and manufactures oncology and non-oncology products. Further, the company offers custom manufacturing of chemicals. The company was incorporated in 1979 and is based in New Delhi, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Shivalik Rasayan Limited reported revenue of ₹3.7B in FY2026 versus ₹2.1B in FY2022, a compound +15.5%/yr. Reported net income was ₹121M in FY2026, compounding −17.0%/yr from FY2022.
Is SHIVALIK fairly valued? → Check now
Similar stocks
6 more Agricultural Inputs stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Corteva, Inc CTVA | $77.46 | $39.29 | -49% |
| Nutrien Ltd NTR | $68.50 | $52.75 | -23% |
| Qinghai Salt Lake Industry Co 000792 | ¥29.03 | ¥21.15 | -27% |
| CF Industries Holdings C1FI34 | R$627.77 | R$947.15 | +51% |
| Yara International ASA YAR | kr 433.40 | kr 67.25 | -84% |
| ICL Group ICL | $5.07 | $2.88 | -43% |
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Shivalik Rasayan Limited (SHIVALIK) undervalued?
What is the fair value of SHIVALIK?
What is the quality score of SHIVALIK?
What is the revenue of Shivalik Rasayan Limited (SHIVALIK)?
What is the net profit margin of SHIVALIK?
Does Shivalik Rasayan Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.